Ibrexafungerp (SCY-078)
Invasive Candidiasis / Invasive Fungal Infections
Phase 3Licensed to GSK for development
Key Facts
Indication
Invasive Candidiasis / Invasive Fungal Infections
Phase
Phase 3
Status
Licensed to GSK for development
Company
About Scynexis
Scynexis has successfully transitioned to a commercial-stage biotech with the FDA approval of BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis, now exclusively licensed to GSK. Its core innovation is the fungerp platform, a first-in-class triterpenoid antifungal with a novel mechanism of action. The company's strategy involves leveraging partnerships for commercialization while advancing a next-generation pipeline, including SCY-247, to tackle life-threatening, drug-resistant invasive fungal infections and, following a recent acquisition, exploring new therapeutic areas like polycystic kidney disease.
View full company profile